For GLP-1 treatment in particular, employers “need to make sure the coverage is married with a patient engagement program, ...

Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42,000 ...

“Two major factors are driving this change,” said Alon Chen, Tastewise co-founder and chief executive officer. “First, the ...

Less than a week after the U.S. Food & Drug Administration (FDA) determined that the shortage of the tirzepatide injection, a glucagon-like peptide ...

The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.

Hims & Hers (NYSE: HIMS) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NYSE: NVO) ...

MGM Resorts plans to stop covering GLP-1 weight loss shots for its employees next year, after it faced constraints in what it ...

An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo ...

Diabetics who must have the medicine to survive fear drugmakers are neglecting their needs in favor of now-popular and profitable weight loss medications. Pharmaceutical companies maintain they are ...

Demand for GLP-1s has not slowed, and employers still have not cracked the code on the perfect solution for medications that represent a growing portion of spend. | LAS VEGAS—Demand for GLP-1s has not ...